Wikipedia:Articles for deletion/Adnexus
From Wikipedia, the free encyclopedia
You have new messages (last change).
- The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.
The result was delete. - Mailer Diablo 04:35, 19 September 2006 (UTC)
[edit] Adnexus
delete non notable biotech company, no notability asserted. No apparent sign of passing WP:CORP. Website ranked in the 1.6millionth, 328 unique Ghits out of 25100, which are mainly internal hits, biotech directory sites, their venture capital partners, or non-us companies with the same name. Company formerly known as 'Compound Therapeutics', 307 unique Ghits/784, of which many are re patent registrations. Alexa ranked in the 2.8 millionth Ohconfucius 10:18, 1 September 2006 (UTC)
- delete as per nominator above. RedWolf 23:23, 8 September 2006 (UTC)
- delete no sign of independent coverage. I'd like to add that the Ghits are often completely irrelevant. For instance, restricting to pages in english gets the Ghits below 1000, 300 unique. Even less with the extra search term biotechnology or by searching for "adnexus therapeutics"Pascal.Tesson 00:39, 9 September 2006 (UTC)
-
- This AfD nomination was incomplete. It is listed now. DumbBOT 15:21, 14 September 2006 (UTC)
- Weak delete. Adnectins do seem to be a novel approach to developing anti-cancer agents, and the company may well attain notability. However, neither adnectin nor their lead product CT-322 get any hits on Medline, suggesting that their development isn't currently very advanced. Espresso Addict 18:11, 15 September 2006 (UTC)
- The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.